SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-19-001776
Filing Date
2019-02-20
Accepted
2019-02-20 08:29:17
Documents
8
Period of Report
2019-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx_8k.htm 8-K 43444
2 NOTE PURCHASE AGREEMENT azrx_ex101.htm EX-10.1 188488
3 SENIOR CONVERTIBLE NOTE A azrx_ex102.htm EX-10.2 128758
4 SENIOR CONVERTIBLE NOTE B, azrx_ex103.htm EX-10.3 128484
5 FORM OF PLEDGE AGREEMENT azrx_ex104.htm EX-10.4 134173
6 WARRANT AMENDMENT azrx_ex105.htm EX-10.5 40181
7 REGISTRATION RIGHTS AGREEMENT azrx_ex106.htm EX-10.6 108763
8 ADDITIONAL EXHIBITS azrx_ex991.htm EX-99.1 24160
  Complete submission text file 0001654954-19-001776.txt   797950
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 19617153
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1